Search results
Results from the WOW.Com Content Network
In the first off-label promotion case ever litigated in a whistleblower suit under the False Claims Act, the settlement was announced after eight years of litigation in May 2004. Warner-Lambert agreed to pay $430 million to resolve all civil and criminal liability, with $24.64 million going to Franklin for his participation in the lawsuit. [2]
By 2009 GSK had paid almost $1 billion to settle paroxetine-related lawsuits related to 450 suicides, withholding data, as well as addiction, antitrust and other claims. An additional 600 unsettled claims related to birth defects. [7] The lawsuits produced thousands of internal company documents, some of which entered the public domain. [33]
The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2]
The lawsuits drove the company to declare bankruptcy in 1995, before it agreed to pay $2.3 billion to settle claims from 240,000 women in amounts ranging from $2,000 to $250,000 each in 2004 ...
Many of these cases have lead to class action lawsuits and proceedings by the Federal Trade ... head to this site to check your VIN and file a claim here. Wells Fargo. Total settlement: $3.7 billion.
Winning or settling your lawsuit can be exhilarating. After you've received the settlement money and paid attorney fees, most people assume that the rest is theirs to keep. However, some ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
In October 2011 the company was sued by the United States Department of Justice (DOJ) for false claims and for a fraudulent scheme to deceive and defraud, [17] and charged that the company touted the study 329 and journal article "that it paid to have drafted and that exaggerated Paxil's efficacy while downplaying risks identified in one of the ...